Company profile
ONCOLYTICS BIOTECH INC
NASDAQ:ONCYBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PELAREOREP | phase3 | — | 15 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07280377 | phase1_2 | active_not_recruiting | 2021-10-27 | 2027-07-30 | Oncolytics Biotech | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab |
| NCT00998322 | phase2 | completed | 2009-10-01 | 2013-12-01 | Oncolytics Biotech | A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma |
| NCT00998192 | phase2 | completed | 2009-10-01 | 2013-09-01 | Oncolytics Biotech | A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung |
| NCT04215146 | phase2 | active_not_recruiting | 2020-06-10 | 2022-08-01 | Oncolytics Biotech | A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study |
| NCT04102618 | — | terminated | 2019-03-29 | 2022-04-20 | Oncolytics Biotech | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer |
FDA applications (0)
No records yet.